<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre=": Mini-Review Diagnostic approaches and potential therapeutic options for coronavirus" exact="disease" post="2019 KhanZ.12GhafoorD.23KhanA.4âˆ—âˆ—UaliyevaD.25KhanS.A.6BilalH.7KhanB.8KhanA.9SajjadW.10âˆ—[1)], [2)], [3)], [4)], [5)], [6)], [7)], [8)],"/>
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="as long as the COVID-19 resource centre remains active. Abstract" exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan"/>
 <result pre="long as the COVID-19 resource centre remains active. Abstract Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan city"/>
 <result pre="as the COVID-19 resource centre remains active. Abstract Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan city of"/>
 <result pre="the COVID-19 resource centre remains active. Abstract Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) emerged in Wuhan city of China"/>
 <result pre="its contagious nature, the virus spreads rapidly and causes coronavirus" exact="disease" post="2019 (COVID-19). The global tally of COVID-19 was 28"/>
 <result pre="especially antiviral drugs and/or vaccines, that could potentially control the" exact="viral" post="spread and manage the ongoing unprecedented global crisis. To"/>
 <result pre="by WHO. Keywords 2019-nCoV Coronavirus 2019 drugs global tally severe" exact="acute" post="respiratory syndrome coronavirus 2 WHO Introduction The recent emergence"/>
 <result pre="WHO. Keywords 2019-nCoV Coronavirus 2019 drugs global tally severe acute" exact="respiratory" post="syndrome coronavirus 2 WHO Introduction The recent emergence of"/>
 <result pre="Keywords 2019-nCoV Coronavirus 2019 drugs global tally severe acute respiratory" exact="syndrome" post="coronavirus 2 WHO Introduction The recent emergence of the"/>
 <result pre="WHO Introduction The recent emergence of the novel coronavirus severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), which caused an outbreak"/>
 <result pre="Introduction The recent emergence of the novel coronavirus severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), which caused an outbreak of"/>
 <result pre="The recent emergence of the novel coronavirus severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), which caused an outbreak of coronavirus"/>
 <result pre="syndrome coronavirus 2 (SARS-CoV-2), which caused an outbreak of coronavirus" exact="disease" post="2019 (COVID-19) in China, has brought about serious threats"/>
 <result pre="appropriate detection assays. SARS-CoV emerged in 2002 and caused the" exact="disease" post="SARS to spread to five continents, with a case"/>
 <result pre="reported in 2004). In 2012, the appearance of Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) in the Arabian Peninsula caused periodic"/>
 <result pre="in 2004). In 2012, the appearance of Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) in the Arabian Peninsula caused periodic epidemics"/>
 <result pre="East respiratory syndrome coronavirus (MERS-CoV) in the Arabian Peninsula caused" exact="periodic" post="epidemics in humans with a mortality rate of 35%."/>
 <result pre="the human population, account for up to 30% of mild" exact="respiratory" post="tract infections, and can lead to serious complications or"/>
 <result pre="children, and in aged and immunocompromised individuals [3,4]. Fig.Â 1" exact="Structural" post="composition (proteins and genetic material) of severe acute respiratory"/>
 <result pre="Fig.Â 1 Structural composition (proteins and genetic material) of severe" exact="acute" post="respiratory syndrome coronavirus 2. Nucleotide detection assay During the"/>
 <result pre="1 Structural composition (proteins and genetic material) of severe acute" exact="respiratory" post="syndrome coronavirus 2. Nucleotide detection assay During the early"/>
 <result pre="Structural composition (proteins and genetic material) of severe acute respiratory" exact="syndrome" post="coronavirus 2. Nucleotide detection assay During the early period"/>
 <result pre="point-of-care molecular devices for fast and accurate diagnosis of SARS-CoV-2" exact="infection" post="[6]. As of 19 April 2020, the US Food"/>
 <result pre="cell. These spikes are the core antigen existing on the" exact="viral" post="surface and the target for neutralizing antibodies during the"/>
 <result pre="polypeptide of âˆ¼1300 amino acids precursor belongs to class I" exact="viral" post="fusion protein [8]. In most of the coronaviruses, the"/>
 <result pre="binding receptors, which enhances the cell surface density of the" exact="viral" post="particles and/or promotes interaction with the fusion receptors. For"/>
 <result pre="sialic acid [18]. In some cases, the attachment of the" exact="viral" post="particle to the host cell is redundant [2]. In"/>
 <result pre="and host cells, which leads to a significant decline in" exact="viral" post="infectivity [17,19,20]. Coronaviruses use multiple fusion receptors, except for"/>
 <result pre="recent study also emphasizes the importance of other cytokines for" exact="viral" post="tissue specificity, including tissue-specific proteases [24,25] (Fig.3 ). Fig.Â"/>
 <result pre="(Fig.3 ). Fig.Â 3 Scheme of investigated antiviral against coronavirus" exact="disease" post="2019, their potential targets and mechanism of action, Names"/>
 <result pre="health centres in Wuhan, China, reported groups of patients with" exact="pneumonia" post="with unfamiliar sources. These were epidemiologically related to a"/>
 <result pre="seafood and wet animal market by the European Centre for" exact="Disease" post="Prevention and Control [26]. Soon after, unbiased sequencing technology"/>
 <result pre="taken from individuals with pneumonia. Epithelial cells from the human" exact="respiratory" post="tract were used to isolate a new coronavirus, initially"/>
 <result pre="[30]. Importantly these isolates resulted in varied cytopathic effects and" exact="viral" post="loads in Vero-E6 cells, which revealed that genetic mutation"/>
 <result pre="pathogenicity of the virus [29,30]. With such vast genetic mutations," exact="recurrent" post="recombination of their genomes, and increased interface activity between"/>
 <result pre="COVID-19 up to 2 September 2020 (https://www.worldometers.info/coronavirus/). Fig.Â 2 Coronavirus" exact="disease" post="2019 continent-wise distribution. Potential drugs against COVID-19 Currently, there"/>
 <result pre="in up to 5%â€&quot;10% of individuals the course of the" exact="disease" post="is severe and can lead to death in vulnerable"/>
 <result pre="excellent efficacy and adequate safety in the treatment of COVID-19-related" exact="pneumonia" post="[37]. Chloroquine phosphate was also used against the SARS-CoV"/>
 <result pre="be used as a possible treatment for individuals with COVID-19-related" exact="pneumonia" post="[40]. Hydroxychloroquine Hydroxychloroquine, an aminoquinoline, is less toxic; with"/>
 <result pre="antimalarial action, hydroxychloroquine is preferred over chloroquine for its low" exact="ocular" post="toxicity [42]. Prolonged treatment (at least 5 years) with"/>
 <result pre="analogue intracellularly activated to adenosine triphosphate analogue, which hinders the" exact="viral" post="RNA polymerase, was initially developed as an antiviral drug"/>
 <result pre="are protease inhibitors that are usually used to treat human" exact="immunodeficiency" post="virus infection with and a booster drug ritonavir. Lopinavir"/>
 <result pre="protease inhibitors that are usually used to treat human immunodeficiency" exact="virus infection" post="with and a booster drug ritonavir. Lopinavir and/or ritonavir"/>
 <result pre="inhibitors that are usually used to treat human immunodeficiency virus" exact="infection" post="with and a booster drug ritonavir. Lopinavir and/or ritonavir"/>
 <result pre="3 days after the onset of lopinavir/ritonavir, in two patients" exact="disease" post="progression was not prevented. The decrease in viral load"/>
 <result pre="two patients disease progression was not prevented. The decrease in" exact="viral" post="load indicated by the circulation threshold in lopinavir/ritonavir-treated and"/>
 <result pre="COVID-19 patients, it was found that improving symptoms and reduced" exact="viral" post="load were not significantly different among the lopinavir/ritonavir treatment"/>
 <result pre="significant difference in the fever reduction rate, cough relief rate," exact="chest" post="CT scan improvement rate, or clinical condition deterioration rate"/>
 <result pre="14%. The patients engaged in this study had a progressive" exact="infection" post="and previously had considerable tissue damage (as shown by"/>
 <result pre="in the control group). Even highly active antibacterial agents have" exact="limited" post="efficacy in advanced bacterial pneumonia [62]. Enhanced clinical recovery"/>
 <result pre="Even highly active antibacterial agents have limited efficacy in advanced" exact="bacterial pneumonia" post="[62]. Enhanced clinical recovery (from 16.0 to 17.0 days)"/>
 <result pre="highly active antibacterial agents have limited efficacy in advanced bacterial" exact="pneumonia" post="[62]. Enhanced clinical recovery (from 16.0 to 17.0 days)"/>
 <result pre="coronavirus, it also exhibits broad-spectrum antiviral activity against influenza virus," exact="respiratory" post="syncytial virus, parainfluenza virus, rotavirus and norovirus [63]. It"/>
 <result pre="is to interfere with the host regulatory pathways associated with" exact="viral" post="replication, rather than virus-specific pathways [64]. Nitazoxanide up-regulates the"/>
 <result pre="mechanism through extensive amplification of cytoplasmic RNA induction and the" exact="type I" post="IFN pathway. Nitazoxanide interferes with viral infection by up-regulating"/>
 <result pre="induction and the type I IFN pathway. Nitazoxanide interferes with" exact="viral infection" post="by up-regulating the specific host mechanism of viral targeting"/>
 <result pre="and the type I IFN pathway. Nitazoxanide interferes with viral" exact="infection" post="by up-regulating the specific host mechanism of viral targeting"/>
 <result pre="with viral infection by up-regulating the specific host mechanism of" exact="viral" post="targeting to avoid host cellular defence [65]. Because of"/>
 <result pre="trials, including randomized controlled trials, to control influenza and other" exact="acute" post="respiratory infections, although the results are either not encouraging"/>
 <result pre="including randomized controlled trials, to control influenza and other acute" exact="respiratory" post="infections, although the results are either not encouraging or"/>
 <result pre="heterodimer (accountable for nuclear importation of integrase protein) and human" exact="immunodeficiency" post="virus 1. This confirms that ivermectin is responsible for"/>
 <result pre="for inhibiting the nuclear import of integrase protein and human" exact="immunodeficiency" post="virus type-1 replication. Other effects of ivermectin have been"/>
 <result pre="than the inhibition of the nuclear import of host and" exact="viral" post="proteins. It has been shown to limit the infection"/>
 <result pre="and viral proteins. It has been shown to limit the" exact="infection" post="of certain RNA viruses (including influenza virus, dengue fever"/>
 <result pre="limit the infection of certain RNA viruses (including influenza virus," exact="dengue fever" post="virus and West Nile virus). Ivermectin has been similarly"/>
 <result pre="A single addition to Vero-hSLAM cells 2 hours after their" exact="infection" post="with SARS-CoV-2 can effectively reduce the viral RNA approximately"/>
 <result pre="hours after their infection with SARS-CoV-2 can effectively reduce the" exact="viral" post="RNA approximately 5000 times for 48 hours. The authors"/>
 <result pre="this may be accomplished by inhibiting importin-Î±/Î²1-mediated nuclear importation of" exact="viral" post="proteins and that this inhibition would disrupt the immune"/>
 <result pre="recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat" exact="rheumatoid arthritis." post="Tocilizumab binds to the soluble and membrane-bound IL-6 receptors,"/>
 <result pre="IL-10, tumour necrosis factor-Î±, interferon-Î³-inducible protein, macrophage inflammatory protein 1Î±," exact="monocyte" post="chemoattractant protein and granulocyte colony-stimulating factor, which suggests a"/>
 <result pre="from individuals who died from severe COVID-19, histological examination revealed" exact="bilateral" post="diffuse alveolar injury with fibrinous mucus-like exudates. Mononuclear inflammatory"/>
 <result pre="individuals who died from severe COVID-19, histological examination revealed bilateral" exact="diffuse" post="alveolar injury with fibrinous mucus-like exudates. Mononuclear inflammatory lymphocytes"/>
 <result pre="that causes an inflammatory storm, which may lead to increased" exact="pulmonary" post="alveolarâ€&quot;capillary blood gas exchange dysfunction, particularly impaired oxygen diffusion,"/>
 <result pre="exchange dysfunction, particularly impaired oxygen diffusion, which ultimately leads to" exact="pulmonary" post="fibrosis and organ failure [71]. A recent study of"/>
 <result pre="deterioration showed a remarkable improvement in body temperature, respiration and" exact="chest" post="tightness after receiving tocilizumab treatment. Of the 21 infected"/>
 <result pre="tocilizumab treatment. Of the 21 infected individuals, 15 recovered from" exact="respiratory" post="diseases, and two were withdrawn from the ventilator after"/>
 <result pre="there were no reports of adverse reactions and subsequent lung" exact="infections" post="and 90.5% of patients displayed significant progress and good"/>
 <result pre="listed in multiple formulations on the WHO Model List of" exact="Essential" post="Medicines, and is currently off-patent and available in most"/>
 <result pre="patients are being treated with steroids. During the trial, a" exact="total" post="of 2104 patients were randomly assigned to receive oral"/>
 <result pre="No benefit was seen in patients who do not require" exact="respiratory" post="support (1.22, 95% CI 0.86â€&quot;1.75; p 0.14) The Oxford"/>
 <result pre="recommended strategy for identifying individuals with COVID-19 is to test" exact="respiratory" post="samples to diagnose the presence of one or several"/>
 <result pre="be transferred to a universal transport medium to preserve the" exact="viral" post="nucleic acid. Samples collected from endotracheal aspirates, sputum and"/>
 <result pre="laboratory for processing, which may be more sensitive than the" exact="upper" post="respiratory tract specimens [79]. Samples are subjected to RNA"/>
 <result pre="for processing, which may be more sensitive than the upper" exact="respiratory" post="tract specimens [79]. Samples are subjected to RNA extraction,"/>
 <result pre="probes for the two regions (N1 and N2) of the" exact="viral" post="nucleocapsid gene, but the WHO PCR primer probes are"/>
 <result pre="have high detection sensitivity and specificity for SARS-CoV-2 and have" exact="limited" post="cross-reactivity with other circulating coronavirus strains, and both have"/>
 <result pre="virus is not possible after day 8 because of high" exact="viral" post="loads of approx. 105 RNA copies per mL. RT-PCR"/>
 <result pre="less than on gene N. Moreover, the correlation between the" exact="viral" post="RNA load and cell culture model for each centre"/>
 <result pre="independently [80]. Antigen-detection-based tests Diagnosis approaches that identify antigens for" exact="respiratory" post="syncytial virus infection or influenza virus infection directly from"/>
 <result pre="Antigen-detection-based tests Diagnosis approaches that identify antigens for respiratory syncytial" exact="virus infection" post="or influenza virus infection directly from clinical samples through"/>
 <result pre="tests Diagnosis approaches that identify antigens for respiratory syncytial virus" exact="infection" post="or influenza virus infection directly from clinical samples through"/>
 <result pre="that identify antigens for respiratory syncytial virus infection or influenza" exact="virus infection" post="directly from clinical samples through immunoassays have been commercialized"/>
 <result pre="identify antigens for respiratory syncytial virus infection or influenza virus" exact="infection" post="directly from clinical samples through immunoassays have been commercialized"/>
 <result pre="low complexity [81]. Current methods for identification of influenza and" exact="respiratory" post="syncytial viruses suffer from suboptimal sensitivity to rule out"/>
 <result pre="respiratory syncytial viruses suffer from suboptimal sensitivity to rule out" exact="disease" post="[82,83], and SARS-CoV-2 may have the same problem. Experiments"/>
 <result pre="However, at the onset of symptoms, when the risk of" exact="viral" post="shedding and transmission seems to be highest, their use"/>
 <result pre="seems to be highest, their use in the diagnosis of" exact="acute" post="infections may be limited [78]. Antibody response to viral"/>
 <result pre="to be highest, their use in the diagnosis of acute" exact="infections" post="may be limited [78]. Antibody response to viral infection"/>
 <result pre="their use in the diagnosis of acute infections may be" exact="limited" post="[78]. Antibody response to viral infection may take several"/>
 <result pre="in the diagnosis of acute infections may be limited [78]." exact="Antibody" post="response to viral infection may take several days to"/>
 <result pre="of acute infections may be limited [78]. Antibody response to" exact="viral infection" post="may take several days to be reliably detected [87]."/>
 <result pre="acute infections may be limited [78]. Antibody response to viral" exact="infection" post="may take several days to be reliably detected [87]."/>
 <result pre="other human coronaviruses are encouraging [88]. In patients with advanced" exact="disease" post="complications during drug therapy, serological testing may be more"/>
 <result pre="to develop serological tests that can accurately assess previous SARS-CoV-2" exact="infection" post="and immunity. In some countries/regions, immunoassays are already on"/>
 <result pre="features of SARS and MERS. Early evidence suggests that initial" exact="chest" post="imaging will show abnormalities in at least 85% of"/>
 <result pre="of patients and that, initially, 75% of patients will have" exact="bilateral" post="lung involvement, most often occurring in the sub-pleural and"/>
 <result pre="bilateral lung involvement, most often occurring in the sub-pleural and" exact="peripheral" post="areas as ground-glass appearance with distortion and convergence. Older"/>
 <result pre="merger can predict a poorer prognosis. In addition to the" exact="acute" post="phase, CT monitoring of individuals recovering from COVID-19 is"/>
 <result pre="people who were initially diagnosed with COVID-19 with a negative" exact="viral" post="swab test showed the importance of early CT results"/>
 <result pre="swab test showed the importance of early CT results for" exact="disease" post="diagnosis. This study suggests that the presence of typical"/>
 <result pre="can show normal findings in 15% of people, so standard" exact="chest" post="imaging examinations cannot eliminate infections. Because chest imaging of"/>
 <result pre="people, so standard chest imaging examinations cannot eliminate infections. Because" exact="chest" post="imaging of individuals with COVID-19 is an important part"/>
 <result pre="may play a key role in reducing the spread of" exact="disease" post="from person to person in the hospital. Radiologists should"/>
 <result pre="to all procedures and techniques to reduce the risk of" exact="infection" post="by medical staff and patients [73]. Vaccines updates SARS-CoV-2"/>
 <result pre="EC50 value in Vero E6 cell Being tested? Inhibitors of" exact="viral" post="RNA polymerase/RNA synthesis Remdesivir PubChem CID:121304016 Image 1 Intravenous"/>
 <result pre="acts as an RdRp inhibitor 61.88 Î¼M Yes Inhibitors of" exact="viral" post="protein synthesis Lopinavir/ritonavir PubChem CID:11979606 Image 3 Orally HIV"/>
 <result pre="Image 3 Orally HIV Inhibition of protease 26.62 Î¼M Yes" exact="Viral" post="entry inhibitors Hydroxychloroquine PubChem CID:3652 Image 4 Orally Antimalarial"/>
 <result pre="PubChem CID:41684 Image 6 Orally Anti-parasitic and antiviral Interference involves" exact="viral" post="replication, amplification of cytoplasmic RNA sensing, and host regulation"/>
 <result pre="amplification of cytoplasmic RNA sensing, and host regulation pathways of" exact="type I" post="interferon 2.12 Î¼M yes Ivermectin PubChem CID:6321424 Image 7"/>
 <result pre="suppressing importin 1 Heterodimer NA yes Immunomodulatory Tocilizumab NA Intravenously" exact="Rheumatoid arthritis;" post="COVID-19 inhibit signal transduction by specifically binding to sIL-6R"/>
 <result pre="evaluation/regulatory status Coronavirus candidate Same platform for non-coronavirus candidates Non-replicating" exact="viral" post="vector ChAdOx1-S University of Oxford/AstraZeneca SARS-CoV-2 Phase 3 ISRCTN89951424Phase2b/32020-001228-32Phase"/>
 <result pre="3 ISRCTN89951424Phase2b/32020-001228-32Phase 1/2 PACTR2020069221651322020-001072-15 MERS, influenza, TB, Chikungunya, Zika, MenB," exact="plague" post="Non- Replicating Viral Vector Adenovirus Type 5 Vector CanSino"/>
 <result pre="PACTR2020069221651322020-001072-15 MERS, influenza, TB, Chikungunya, Zika, MenB, plague Non- Replicating" exact="Viral" post="Vector Adenovirus Type 5 Vector CanSino Biological Inc./Beijing Institute"/>
 <result pre="TB, Chikungunya, Zika, MenB, plague Non- Replicating Viral Vector Adenovirus" exact="Type 5" post="Vector CanSino Biological Inc./Beijing Institute of Biotechnology SARS-CoV-2 Phase"/>
 <result pre="Inactivated InactivatedÂ +Â alum Sinovac SARS-CoV-2 Phase 1/2 NCT04383574NCT04352608 SARS" exact="Protein" post="Subunit Full-length recombinant SARS CoV-2glycoprotein nanoparticle vaccine adjuvanted withMatrix"/>
 <result pre="ReplicatingViral Vector Adeno-based Gamaleya Research Institute SARS-CoV-2 Phase 1 NCT04436471NCT04437875" exact="Protein" post="Subunit Native like Trimeric subunit Spike Protein vaccine Clover"/>
 <result pre="Phase 1 NCT04436471NCT04437875 Protein Subunit Native like Trimeric subunit Spike" exact="Protein" post="vaccine Clover Biopharmaceuticals Inc./GSK/Dynavax SARS-CoV-2 Phase 1 NCT04405908 HIV,"/>
 <result pre="Clover Biopharmaceuticals Inc./GSK/Dynavax SARS-CoV-2 Phase 1 NCT04405908 HIV, REV Influenza" exact="Protein" post="Subunit Adjuvanted recombinant protein (RBD-Dimer) Anhui Zhifei Longcom Biopharmaceutical/Institute"/>
 <result pre="of Microbiology, Chinese Academy ofSciences SARS-CoV-2 Phase 1 NCT04445194 MERS" exact="Protein" post="Subunit Recombinant spike protein with Advaxâ&quot;¢Adjuvant Vaxine Pty Ltd/Medytox"/>
 <result pre="fever virus; DENV, dengue virus; EBOV, Ebola virus; HIV, human" exact="immunodeficiency" post="virus; HPV, human papillomavirus; Inf (H7N9), influenza virus H7N9;"/>
 <result pre="influenza virus H7N9; LASV, Lassa mammarenavirus; MARV, Marburg virus; MenB," exact="meningitis" post="B; MERS, Middle East respiratory syndrome; NIPV, Nipah virus;"/>
 <result pre="mammarenavirus; MARV, Marburg virus; MenB, meningitis B; MERS, Middle East" exact="respiratory" post="syndrome; NIPV, Nipah virus; RABV, rabies virus; REV, reticuloendothelial"/>
 <result pre="B; MERS, Middle East respiratory syndrome; NIPV, Nipah virus; RABV," exact="rabies" post="virus; REV, reticuloendothelial virus; RSV, respiratory syncytial virus; SARS,"/>
 <result pre="NIPV, Nipah virus; RABV, rabies virus; REV, reticuloendothelial virus; RSV," exact="respiratory" post="syncytial virus; SARS, severe acute respiratory syndrome; TB, tuberculosis;"/>
 <result pre="virus; REV, reticuloendothelial virus; RSV, respiratory syncytial virus; SARS, severe" exact="acute" post="respiratory syndrome; TB, tuberculosis; VZV, varicella zoster virus. Conclusion"/>
 <result pre="REV, reticuloendothelial virus; RSV, respiratory syncytial virus; SARS, severe acute" exact="respiratory" post="syndrome; TB, tuberculosis; VZV, varicella zoster virus. Conclusion and"/>
 <result pre="virus; SARS, severe acute respiratory syndrome; TB, tuberculosis; VZV, varicella" exact="zoster" post="virus. Conclusion and perspective There is an intensifying health"/>
 <result pre="drugs but also the development of new anti-COVID-19 treatments. The" exact="absence of" post="effective drugs is the prime reason for the rapid"/>
 <result pre="been reported to have strong inÂ vitro activity, there are" exact="limited" post="options with clinical potential. Treatment options are now available"/>
 <result pre="SARS-like coronavirus that uses the ACE2 receptorNature5037477201353553824172901 2HaagmansB.L.Al DhahiryS.H.ReuskenC.B.RajV.S.GalianoM.MyersR.Middle East" exact="respiratory" post="syndrome coronavirus in dromedary camels: an outbreak investigationLancet Infect"/>
 <result pre="coronavirus that uses the ACE2 receptorNature5037477201353553824172901 2HaagmansB.L.Al DhahiryS.H.ReuskenC.B.RajV.S.GalianoM.MyersR.Middle East respiratory" exact="syndrome" post="coronavirus in dromedary camels: an outbreak investigationLancet Infect Dis14201414014524355866"/>
 <result pre="genetic recombination, and pathogenesis of coronavirusesTrends Microbiol24201649050227012512 4IsaacsD.FlowersD.ClarkeJ.R.ValmanH.B.MacNaughtonM.R.Epidemiology of coronavirus" exact="respiratory" post="infectionsArch Dis Child5819835005036307189 5YuF.YanL.WangN.YangS.WangL.TangY.Quantitative detection and viral load analysis"/>
 <result pre="4IsaacsD.FlowersD.ClarkeJ.R.ValmanH.B.MacNaughtonM.R.Epidemiology of coronavirus respiratory infectionsArch Dis Child5819835005036307189 5YuF.YanL.WangN.YangS.WangL.TangY.Quantitative detection and" exact="viral" post="load analysis of SARS-CoV-2 in infected patientsClin Infect Dis"/>
 <result pre="7ParkG.S.KuK.BaekS.H.KimS.J.KimS.I.KimB.T.Development of reverse transcription loop-mediated isothermal amplification assays targeting severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2)JÂ Mol Diagn22202072973532276051 8BoschB.J.van der"/>
 <result pre="of reverse transcription loop-mediated isothermal amplification assays targeting severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2)JÂ Mol Diagn22202072973532276051 8BoschB.J.van der ZeeR.de"/>
 <result pre="reverse transcription loop-mediated isothermal amplification assays targeting severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2)JÂ Mol Diagn22202072973532276051 8BoschB.J.van der ZeeR.de HaanC.A.RottierP.J.The"/>
 <result pre="is an attachment factor for foamy virus entryJÂ Virol862012100281003522787203 20ConnellB.J.Lortat-JacobH.Human" exact="immunodeficiency" post="virus and heparan sulfate: from attachment to entry inhibitionFront"/>
 <result pre="the emerging human coronavirus-EMCNature4957440201325125423486063 24MilletJ.K.WhittakerG.R.Host cell entry of Middle East" exact="respiratory" post="syndrome coronavirus after two-step, furin-mediated activation of the spike"/>
 <result pre="emerging human coronavirus-EMCNature4957440201325125423486063 24MilletJ.K.WhittakerG.R.Host cell entry of Middle East respiratory" exact="syndrome" post="coronavirus after two-step, furin-mediated activation of the spike proteinProc"/>
 <result pre="potential therapeutic agentsCurr Pharmaceut Des.132007405414 26collab: ECDC. European Centre for" exact="Disease" post="Prevention and ControlCluster of pneumonia cases caused by a"/>
 <result pre="26collab: ECDC. European Centre for Disease Prevention and ControlCluster of" exact="pneumonia" post="cases caused by a novel coronavirus, Wuhan, China2020ECDCSolna 27DuffyS.Why"/>
 <result pre="Microbiol17201918119230531947 32WongG.LiuW.LiuY.ZhouB.BiY.GaoG.F.MERS, SARS, and Ebola: the role of super-spreaders in" exact="infectious" post="diseaseCell Host Microbe18201539840126468744 33SabawoonW.Differences by country-level income in COVID-19"/>
 <result pre="center experience202010.21203/rs.3.rs-37618/v1 35Solidarityâ€� clinical trial for COVID-19 treatments2020int/emergencies/diseases/novel-coronavirus-/global-research-on-novel-coronavirusâ€&quot;ncov/solidarity-clinical-trial-for-covid-19-treatments WHOJWHOSrGWAfhww 36McCrearyE.K.PogueJ.M.Coronavirus" exact="disease" post="2019 treatment: a review of early and emerging optionsOpen"/>
 <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studiesBiosci Trends142020727332074550 38TortoriciM.A.WallsA.C.LangY.WangC.LiZ.KoerhuisD.Structural basis for human coronavirus"/>
 <result pre="neurological diseases: a mini-reviewClin Drug Invest382018653671 40SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of chloroquine on" exact="viral" post="infections: an old drug against today's diseases?Lancet Infect Dis3200372272714592603"/>
 <result pre="against hand, foot and mouth diseaseAntivir Res149201814314929175128 43SahraeiZ.ShabaniM.ShokouhiS.SaffaeiA.Aminoquinolines against coronavirus" exact="disease" post="2019 (COVID-19): chloroquine or hydroxychloroquineInt J Antimicrob Agents55202010594532194152 44MillionM.GautretP.ColsonP.RousselY.DubourgG.ChabriereE.Clinical"/>
 <result pre="infectionClin Pharmacol Ther1082202024224732246834 52FurutaY.KomenoT.NakamuraT.Favipiravir (T-705), a broad spectrum inhibitor of" exact="viral" post="RNA polymeraseProc Jpn Acad Ser B, Phys Biol Sci932017449463"/>
 <result pre="Phys Biol Sci932017449463 53BaiC.Q.MuJ.S.KargboD.SongY.B.NiuW.K.NieW.M.Clinical and virological characteristics of Ebola virus" exact="disease" post="patients treated with favipiravir (T-705)-Sierra Leone, 2014Clin Infect Dis6320161288129427553371"/>
 <result pre="2014Clin Infect Dis6320161288129427553371 54CorrectionExperimental treatment with favipiravir for Ebola virus" exact="disease" post="(the JIKI trial): a historically controlled, single-arm proof-of-concept trial"/>
 <result pre="replication inÂ vitroAntivir Res178202010478632251767 56DaviesR.ChoyE.Clinical experience of IL-6 blockade in" exact="rheumatic" post="diseasesâ€&quot;implications on IL-6 biology and disease pathogenesisSemin Immunol2620149710424389239 57YoungB.E.OngS.W.X.KalimuddinS.LowJ.G.TanS.Y.LohJ.Epidemiologic"/>
 <result pre="of IL-6 blockade in rheumatic diseasesâ€&quot;implications on IL-6 biology and" exact="disease" post="pathogenesisSemin Immunol2620149710424389239 57YoungB.E.OngS.W.X.KalimuddinS.LowJ.G.TanS.Y.LohJ.Epidemiologic features and clinical course of patients"/>
 <result pre="Dis34202010166332289548 59YeX.T.LuoY.L.XiaS.C.SunQ.F.DingJ.G.ZhouY.Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus" exact="disease" post="2019Eur Rev Med Pharmacol Sci2420203390339632271456 60ChenC.Y.WangF.L.LinC.C.Chronic hydroxychloroquine use associated"/>
 <result pre="a new drug candidate for the treatment of Middle East" exact="respiratory" post="syndrome coronavirusJÂ Infect Public Health9201622723027095301 65JasenoskyL.D.CadenaC.MireC.E.BorisevichV.HaridasV.RanjbarS.The FDA-approved oral drug"/>
 <result pre="new drug candidate for the treatment of Middle East respiratory" exact="syndrome" post="coronavirusJÂ Infect Public Health9201622723027095301 65JasenoskyL.D.CadenaC.MireC.E.BorisevichV.HaridasV.RanjbarS.The FDA-approved oral drug nitazoxanide"/>
 <result pre="of efficacy of ivermectin for prevention of a lethal Zika" exact="virus infection" post="in a murine systemDiagn Microbiol Infect Dis952019384031097261 68KalyL.RosnerI.Tocilizumabâ€&quot;a novel"/>
 <result pre="efficacy of ivermectin for prevention of a lethal Zika virus" exact="infection" post="in a murine systemDiagn Microbiol Infect Dis952019384031097261 68KalyL.RosnerI.Tocilizumabâ€&quot;a novel"/>
 <result pre="murine systemDiagn Microbiol Infect Dis952019384031097261 68KalyL.RosnerI.Tocilizumabâ€&quot;a novel therapy for non-organ-specific" exact="autoimmune" post="diseasesBest Practice Research Clin Rheumatol262012157165 69CoperchiniF.ChiovatoL.CroceL.MagriF.RotondiM.The cytokine storm in"/>
 <result pre="systemCytokine Growth Factor Rev532020253232446778 70XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.Pathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndromeLancet Resp Med82020420422 71ZhouY.FuB.ZhengX.WangD.ZhaoC.qiY.Aberrant pathogenic GM-CSF+ T"/>
 <result pre="Growth Factor Rev532020253232446778 70XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.Pathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndromeLancet Resp Med82020420422 71ZhouY.FuB.ZhengX.WangD.ZhaoC.qiY.Aberrant pathogenic GM-CSF+ T cells"/>
 <result pre="pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe" exact="pulmonary" post="syndrome patients of a new coronavirus2020202002.12.945576 72XuX.HanM.LiT.SunW.WangD.FuB.Effective treatment of"/>
 <result pre="GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary" exact="syndrome" post="patients of a new coronavirus2020202002.12.945576 72XuX.HanM.LiT.SunW.WangD.FuB.Effective treatment of severe"/>
 <result pre="73WangD.HuB.HuC.ZhuF.LiuX.ZhangJ.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected" exact="pneumonia" post="in Wuhan, ChinaJAMA32320201061106932031570 74WHOWHO, Adapted from WHO welcomes preliminary"/>
 <result pre="77CormanV.M.LandtO.KaiserM.MolenkampR.MeijerA.ChuD.K.Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCREurosurveillance2532020 78ZouL.RuanF.HuangM.LiangL.HuangH.HongZ.SARS-CoV-2" exact="viral" post="load in upper respiratory specimens of infected patientsNÂ Engl"/>
 <result pre="novel coronavirus (2019-nCoV) by real-time RT-PCREurosurveillance2532020 78ZouL.RuanF.HuangM.LiangL.HuangH.HongZ.SARS-CoV-2 viral load in" exact="upper" post="respiratory specimens of infected patientsNÂ Engl J Med38220201177117932074444 79WangW.XuY.GaoR.LuR.HanK.WuG.Detection"/>
 <result pre="coronavirus (2019-nCoV) by real-time RT-PCREurosurveillance2532020 78ZouL.RuanF.HuangM.LiangL.HuangH.HongZ.SARS-CoV-2 viral load in upper" exact="respiratory" post="specimens of infected patientsNÂ Engl J Med38220201177117932074444 79WangW.XuY.GaoR.LuR.HanK.WuG.Detection of"/>
 <result pre="as a management tool for discharge of SARS-CoV-2 patients from" exact="infectious disease" post="wardsEur J Clin Microbiol Infect Dis3920201059106132342252 81PrendergastC.PapenburgJ.Rapid antigen-based testing"/>
 <result pre="a management tool for discharge of SARS-CoV-2 patients from infectious" exact="disease" post="wardsEur J Clin Microbiol Infect Dis3920201059106132342252 81PrendergastC.PapenburgJ.Rapid antigen-based testing"/>
 <result pre="wardsEur J Clin Microbiol Infect Dis3920201059106132342252 81PrendergastC.PapenburgJ.Rapid antigen-based testing for" exact="respiratory" post="syncytial virus: moving diagnostics from bench to bedside?Future Microbiol8201343544423534357"/>
 <result pre="bedside?Future Microbiol8201343544423534357 82ChartrandC.TremblayN.RenaudC.PapenburgJ.Diagnostic accuracy of rapid antigen detection tests for" exact="respiratory" post="syncytial virus infection: systematic review and meta-analysisJÂ Clin Microbiol5320153738374926354816"/>
 <result pre="83MerckxJ.WaliR.SchillerI.CayaC.GoreG.C.ChartrandC.Diagnostic accuracy of novel and traditional rapid tests for influenza" exact="infection" post="compared with reverse transcriptase polymerase chain reaction: a systematic"/>
 <result pre="a systematic review and meta-analysisAnn Intern Med167201739440928869986 84LauS.K.WooP.C.WongB.H.TsoiH.W.WooG.K.PoonR.W.Detection of severe" exact="acute" post="respiratory syndrome (SARS) coronavirus nucleocapsid protein in sars patients"/>
 <result pre="systematic review and meta-analysisAnn Intern Med167201739440928869986 84LauS.K.WooP.C.WongB.H.TsoiH.W.WooG.K.PoonR.W.Detection of severe acute" exact="respiratory" post="syndrome (SARS) coronavirus nucleocapsid protein in sars patients by"/>
 <result pre="review and meta-analysisAnn Intern Med167201739440928869986 84LauS.K.WooP.C.WongB.H.TsoiH.W.WooG.K.PoonR.W.Detection of severe acute respiratory" exact="syndrome" post="(SARS) coronavirus nucleocapsid protein in sars patients by enzyme-linked"/>
 <result pre="85ChenY.ChanK.H.KangY.ChenH.LukH.K.PoonR.W.AÂ sensitive and specific antigen detection assay for Middle East" exact="respiratory" post="syndrome coronavirusEmerg Microb Infect42015e26 86SheridanC.Fast, portable tests come online"/>
 <result pre="sensitive and specific antigen detection assay for Middle East respiratory" exact="syndrome" post="coronavirusEmerg Microb Infect42015e26 86SheridanC.Fast, portable tests come online to"/>
 <result pre="pandemicNat Biotechnol38202051551832203294 87GuoL.RenL.YangS.XiaoM.ChangD.YangF.Profiling early humoral response to diagnose novel coronavirus" exact="disease" post="(COVID-19)Clin Infect Dis2020 88PatrickD.M.PetricM.SkowronskiD.M.GuaspariniR.BoothT.F.KrajdenM.An outbreak of human coronavirus OC43"/>
 <result pre="disease (COVID-19)Clin Infect Dis2020 88PatrickD.M.PetricM.SkowronskiD.M.GuaspariniR.BoothT.F.KrajdenM.An outbreak of human coronavirus OC43" exact="infection" post="and serological cross-reactivity with SARS coronavirusCan J Infect Dis"/>
 <result pre="SARS coronavirusCan J Infect Dis Med Microbiol17200633033618382647 89ToK.K.TsangO.T.LeungW.S.TamA.R.WuT.C.LungD.C.Temporal profiles of" exact="viral" post="load in posterior oropharyngeal saliva samples and serum antibody"/>
 <result pre="Infect Dis Med Microbiol17200633033618382647 89ToK.K.TsangO.T.LeungW.S.TamA.R.WuT.C.LungD.C.Temporal profiles of viral load in" exact="posterior" post="oropharyngeal saliva samples and serum antibody responses during infection"/>
 <result pre="in posterior oropharyngeal saliva samples and serum antibody responses during" exact="infection" post="by SARS-CoV-2: an observational cohort studyLancet Infect Dis20202056557432213337 90HosseinyM.KoorakiS.GholamrezanezhadA.ReddyS.MyersL.Radiology"/>
 <result pre="an observational cohort studyLancet Infect Dis20202056557432213337 90HosseinyM.KoorakiS.GholamrezanezhadA.ReddyS.MyersL.Radiology perspective of coronavirus" exact="disease" post="2019 (COVID-19): lessons from severe acute respiratory syndrome and"/>
 <result pre="90HosseinyM.KoorakiS.GholamrezanezhadA.ReddyS.MyersL.Radiology perspective of coronavirus disease 2019 (COVID-19): lessons from severe" exact="acute" post="respiratory syndrome and middle east respiratory syndromeAm J Roentgenol21420201078108232108495"/>
 <result pre="perspective of coronavirus disease 2019 (COVID-19): lessons from severe acute" exact="respiratory" post="syndrome and middle east respiratory syndromeAm J Roentgenol21420201078108232108495 91XieX.ZhongZ.ZhaoW.ZhengC.WangF.LiuJ.Chest"/>
 <result pre="of coronavirus disease 2019 (COVID-19): lessons from severe acute respiratory" exact="syndrome" post="and middle east respiratory syndromeAm J Roentgenol21420201078108232108495 91XieX.ZhongZ.ZhaoW.ZhengC.WangF.LiuJ.Chest CT"/>
 <result pre="(COVID-19): lessons from severe acute respiratory syndrome and middle east" exact="respiratory" post="syndromeAm J Roentgenol21420201078108232108495 91XieX.ZhongZ.ZhaoW.ZhengC.WangF.LiuJ.Chest CT for typical 2019-nCoV pneumonia:"/>
</results>
